USFDA's Advisory Committee (ODAC) unanimously voted 16-0 in favor of approval of Biocon/ Mylan's MYL-1401O, biosimilar Trastuzumab (Herceptin) for all indications. It determined MYL-1401O is highly similar to Herceptin. We believe positive ODAC ruling paves way for the approval in US (albeit GMP..